{
    "markdown": "<a id='a78105fa-ec68-4747-ae9c-a786030fb52e'></a>\n\n<::logo: Takeda Pharmaceuticals North America, Inc.\nTakeda, TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.\nThe logo features the word \"Takeda\" in a stylized font within a dark, elongated oval shape, with the full company name in capital letters below.::>\n\n<a id='d9fc606c-46eb-44e2-a6f6-c178a420b8c1'></a>\n\nNovember 18, 2002\n\n<a id='4237a84f-046e-4406-b226-80fd8e097100'></a>\n\nDavid Orloff, M.D.\nDivision of Metabolic & Endocrine Drug Products (HFD-510)\nOffice of Drug Evaluation II\nCenter for Drug Evaluation & Research\nDocument Control Room 14B-19\nFood and Drug Administration\n5600 Fishers Lane\nRockville, MD 20857\n\n<a id='c3a05549-584b-494d-99c8-a707125bdd7f'></a>\n\nACTOS\u00ae (pioglitazone HCl) Tablets, 15, 30 and 45-mg\nSerial No. 501\n\n<a id='2b8fe70d-9bc3-4d31-b303-dec2a2d005c4'></a>\n\nResponse to FDA Request for Information\n\n<a id='144c5eef-182b-440c-8400-1b12e99e9bbf'></a>\n\nDear Dr. Orloff:\n\nReference is made to a telephone conference call held between Drs. Orloff, Misbin and El-Hage and Ms. Jena Weber, of the Division and representatives from Takeda Pharmaceuticals North America, Inc. (TPNA) on July 31, August 13, November 1 and 6, 2002 and submissions made to the above noted IND on August 28, and September 27, 2002 (Serial Nos. 485 and 490, respectively).\n\n<a id='f0a88e60-5d05-4d2b-bb7f-2c736fbb322a'></a>\n\nDuring the conference call with Division members on November 6th, Dr. Orloff\nrequested that TPNA break the study medication blind on the two patients that were\nreported to the IND on September 27th. The purpose of this submission is to comply with\nthe Division request. Information on these patients was previously submitted to the\nAgency in a blinded fashion as Serial Number 490. The case histories followed by the\ndrug treatment are detailed below. Both patients have been discontinued from the study.\n\n<a id='b52c92a5-9e84-4015-b875-e9bed7561b94'></a>\n\nCase Number One:\n\nA 58 year old male, enrolled in the study for 103 days, was hospitalized for a urinary tract obstruction, which was later diagnosed as bladder cancer. This patient had a two year intermittent history of hematuria with dysuria and urinary retention, urinary tract infections, hemorrhagic cysitis and enlarged prostate. The patient has been discontinued from the trial and there is no available information on tobacco use or exposure to other chemicals.\n\n<a id='9429d7cc-5188-41be-a219-7de88f27b469'></a>\n\nDrug Treatment: Pioglitazone HCl\n\n<a id='dc372b44-8fbc-4324-bfe1-a7699317a68e'></a>\n\n<::attestation: Stamp\nStamped\nReadable Text: EXHIBIT, Bhattacharya, 39, 10-27-13, ADDER\nA rectangular stamp with a thick black border, containing the word \"EXHIBIT\" at the top, followed by handwritten text \"Bhattacharya\", \"39\", and \"10-27-13\". The word \"ADDER\" is vertically oriented on the left side of the stamp. The stamp is centrally located in the image.::>\n\n<a id='78dc223a-9ccd-475c-af3c-12e803aeb7e7'></a>\n\n475 Half Day Road. Suite 500 Lincolnshire, Illinois 60069 Phone: 847-363-3000\n\n<a id='4bf7dce2-d168-46c0-a22d-76ff969c592f'></a>\n\nConfidential -- Subject to Protective Order\n\n<a id='f770cbf5-5959-40e8-978f-de2934d22bdc'></a>\n\nTAK-INDNDA-01273547\nProduced in MDL on 09/11/2012\n\n<a id='9934a470-964e-42fe-82c8-40083171a9e2'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/gyjf0226 P167900001",
    "chunks": [
        {
            "markdown": "<a id='a78105fa-ec68-4747-ae9c-a786030fb52e'></a>\n\n<::logo: Takeda Pharmaceuticals North America, Inc.\nTakeda, TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.\nThe logo features the word \"Takeda\" in a stylized font within a dark, elongated oval shape, with the full company name in capital letters below.::>",
            "type": "logo",
            "id": "a78105fa-ec68-4747-ae9c-a786030fb52e",
            "grounding": {
                "box": {
                    "left": 0.29892200231552124,
                    "top": 0.03721657022833824,
                    "right": 0.5878741145133972,
                    "bottom": 0.09662145376205444
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='d9fc606c-46eb-44e2-a6f6-c178a420b8c1'></a>\n\nNovember 18, 2002",
            "type": "text",
            "id": "d9fc606c-46eb-44e2-a6f6-c178a420b8c1",
            "grounding": {
                "box": {
                    "left": 0.11107990145683289,
                    "top": 0.14249640703201294,
                    "right": 0.26556310057640076,
                    "bottom": 0.16295117139816284
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='4237a84f-046e-4406-b226-80fd8e097100'></a>\n\nDavid Orloff, M.D.\nDivision of Metabolic & Endocrine Drug Products (HFD-510)\nOffice of Drug Evaluation II\nCenter for Drug Evaluation & Research\nDocument Control Room 14B-19\nFood and Drug Administration\n5600 Fishers Lane\nRockville, MD 20857",
            "type": "text",
            "id": "4237a84f-046e-4406-b226-80fd8e097100",
            "grounding": {
                "box": {
                    "left": 0.11240692436695099,
                    "top": 0.18957534432411194,
                    "right": 0.5743260383605957,
                    "bottom": 0.31996098160743713
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='c3a05549-584b-494d-99c8-a707125bdd7f'></a>\n\nACTOS\u00ae (pioglitazone HCl) Tablets, 15, 30 and 45-mg\nSerial No. 501",
            "type": "text",
            "id": "c3a05549-584b-494d-99c8-a707125bdd7f",
            "grounding": {
                "box": {
                    "left": 0.11348368227481842,
                    "top": 0.3289727568626404,
                    "right": 0.5275429487228394,
                    "bottom": 0.36630910634994507
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='2b8fe70d-9bc3-4d31-b303-dec2a2d005c4'></a>\n\nResponse to FDA Request for Information",
            "type": "text",
            "id": "2b8fe70d-9bc3-4d31-b303-dec2a2d005c4",
            "grounding": {
                "box": {
                    "left": 0.4056697189807892,
                    "top": 0.377616286277771,
                    "right": 0.7431739568710327,
                    "bottom": 0.3979176878929138
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='144c5eef-182b-440c-8400-1b12e99e9bbf'></a>\n\nDear Dr. Orloff:\n\nReference is made to a telephone conference call held between Drs. Orloff, Misbin and El-Hage and Ms. Jena Weber, of the Division and representatives from Takeda Pharmaceuticals North America, Inc. (TPNA) on July 31, August 13, November 1 and 6, 2002 and submissions made to the above noted IND on August 28, and September 27, 2002 (Serial Nos. 485 and 490, respectively).",
            "type": "text",
            "id": "144c5eef-182b-440c-8400-1b12e99e9bbf",
            "grounding": {
                "box": {
                    "left": 0.11296775937080383,
                    "top": 0.39368584752082825,
                    "right": 0.7782700061798096,
                    "bottom": 0.5074049830436707
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='f0a88e60-5d05-4d2b-bb7f-2c736fbb322a'></a>\n\nDuring the conference call with Division members on November 6th, Dr. Orloff\nrequested that TPNA break the study medication blind on the two patients that were\nreported to the IND on September 27th. The purpose of this submission is to comply with\nthe Division request. Information on these patients was previously submitted to the\nAgency in a blinded fashion as Serial Number 490. The case histories followed by the\ndrug treatment are detailed below. Both patients have been discontinued from the study.",
            "type": "text",
            "id": "f0a88e60-5d05-4d2b-bb7f-2c736fbb322a",
            "grounding": {
                "box": {
                    "left": 0.11335068941116333,
                    "top": 0.5169841051101685,
                    "right": 0.7794840931892395,
                    "bottom": 0.6182799339294434
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='b52c92a5-9e84-4015-b875-e9bed7561b94'></a>\n\nCase Number One:\n\nA 58 year old male, enrolled in the study for 103 days, was hospitalized for a urinary tract obstruction, which was later diagnosed as bladder cancer. This patient had a two year intermittent history of hematuria with dysuria and urinary retention, urinary tract infections, hemorrhagic cysitis and enlarged prostate. The patient has been discontinued from the trial and there is no available information on tobacco use or exposure to other chemicals.",
            "type": "text",
            "id": "b52c92a5-9e84-4015-b875-e9bed7561b94",
            "grounding": {
                "box": {
                    "left": 0.11507201194763184,
                    "top": 0.6434211730957031,
                    "right": 0.7783000469207764,
                    "bottom": 0.7728440761566162
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='9429d7cc-5188-41be-a219-7de88f27b469'></a>\n\nDrug Treatment: Pioglitazone HCl",
            "type": "text",
            "id": "9429d7cc-5188-41be-a219-7de88f27b469",
            "grounding": {
                "box": {
                    "left": 0.14175762236118317,
                    "top": 0.7826957702636719,
                    "right": 0.40267765522003174,
                    "bottom": 0.8042774200439453
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='dc372b44-8fbc-4324-bfe1-a7699317a68e'></a>\n\n<::attestation: Stamp\nStamped\nReadable Text: EXHIBIT, Bhattacharya, 39, 10-27-13, ADDER\nA rectangular stamp with a thick black border, containing the word \"EXHIBIT\" at the top, followed by handwritten text \"Bhattacharya\", \"39\", and \"10-27-13\". The word \"ADDER\" is vertically oriented on the left side of the stamp. The stamp is centrally located in the image.::>",
            "type": "attestation",
            "id": "dc372b44-8fbc-4324-bfe1-a7699317a68e",
            "grounding": {
                "box": {
                    "left": 0.7488587498664856,
                    "top": 0.8026862144470215,
                    "right": 0.9561989903450012,
                    "bottom": 0.904842734336853
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='78dc223a-9ccd-475c-af3c-12e803aeb7e7'></a>\n\n475 Half Day Road. Suite 500 Lincolnshire, Illinois 60069 Phone: 847-363-3000",
            "type": "text",
            "id": "78dc223a-9ccd-475c-af3c-12e803aeb7e7",
            "grounding": {
                "box": {
                    "left": 0.16681012511253357,
                    "top": 0.8754689693450928,
                    "right": 0.7227685451507568,
                    "bottom": 0.8921399116516113
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='4bf7dce2-d168-46c0-a22d-76ff969c592f'></a>\n\nConfidential -- Subject to Protective Order",
            "type": "marginalia",
            "id": "4bf7dce2-d168-46c0-a22d-76ff969c592f",
            "grounding": {
                "box": {
                    "left": 0.03399725258350372,
                    "top": 0.922006368637085,
                    "right": 0.3084467649459839,
                    "bottom": 0.9397284984588623
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='f770cbf5-5959-40e8-978f-de2934d22bdc'></a>\n\nTAK-INDNDA-01273547\nProduced in MDL on 09/11/2012",
            "type": "text",
            "id": "f770cbf5-5959-40e8-978f-de2934d22bdc",
            "grounding": {
                "box": {
                    "left": 0.7016910314559937,
                    "top": 0.9200401306152344,
                    "right": 0.9225085973739624,
                    "bottom": 0.9526458978652954
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='9934a470-964e-42fe-82c8-40083171a9e2'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/gyjf0226 P167900001",
            "type": "marginalia",
            "id": "9934a470-964e-42fe-82c8-40083171a9e2",
            "grounding": {
                "box": {
                    "left": 0.2208075225353241,
                    "top": 0.9794996976852417,
                    "right": 0.7793192863464355,
                    "bottom": 0.9998054504394531
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='a78105fa-ec68-4747-ae9c-a786030fb52e'></a>\n\n<::logo: Takeda Pharmaceuticals North America, Inc.\nTakeda, TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.\nThe logo features the word \"Takeda\" in a stylized font within a dark, elongated oval shape, with the full company name in capital letters below.::>\n\n<a id='d9fc606c-46eb-44e2-a6f6-c178a420b8c1'></a>\n\nNovember 18, 2002\n\n<a id='4237a84f-046e-4406-b226-80fd8e097100'></a>\n\nDavid Orloff, M.D.\nDivision of Metabolic & Endocrine Drug Products (HFD-510)\nOffice of Drug Evaluation II\nCenter for Drug Evaluation & Research\nDocument Control Room 14B-19\nFood and Drug Administration\n5600 Fishers Lane\nRockville, MD 20857\n\n<a id='c3a05549-584b-494d-99c8-a707125bdd7f'></a>\n\nACTOS\u00ae (pioglitazone HCl) Tablets, 15, 30 and 45-mg\nSerial No. 501\n\n<a id='2b8fe70d-9bc3-4d31-b303-dec2a2d005c4'></a>\n\nResponse to FDA Request for Information\n\n<a id='144c5eef-182b-440c-8400-1b12e99e9bbf'></a>\n\nDear Dr. Orloff:\n\nReference is made to a telephone conference call held between Drs. Orloff, Misbin and El-Hage and Ms. Jena Weber, of the Division and representatives from Takeda Pharmaceuticals North America, Inc. (TPNA) on July 31, August 13, November 1 and 6, 2002 and submissions made to the above noted IND on August 28, and September 27, 2002 (Serial Nos. 485 and 490, respectively).\n\n<a id='f0a88e60-5d05-4d2b-bb7f-2c736fbb322a'></a>\n\nDuring the conference call with Division members on November 6th, Dr. Orloff\nrequested that TPNA break the study medication blind on the two patients that were\nreported to the IND on September 27th. The purpose of this submission is to comply with\nthe Division request. Information on these patients was previously submitted to the\nAgency in a blinded fashion as Serial Number 490. The case histories followed by the\ndrug treatment are detailed below. Both patients have been discontinued from the study.\n\n<a id='b52c92a5-9e84-4015-b875-e9bed7561b94'></a>\n\nCase Number One:\n\nA 58 year old male, enrolled in the study for 103 days, was hospitalized for a urinary tract obstruction, which was later diagnosed as bladder cancer. This patient had a two year intermittent history of hematuria with dysuria and urinary retention, urinary tract infections, hemorrhagic cysitis and enlarged prostate. The patient has been discontinued from the trial and there is no available information on tobacco use or exposure to other chemicals.\n\n<a id='9429d7cc-5188-41be-a219-7de88f27b469'></a>\n\nDrug Treatment: Pioglitazone HCl\n\n<a id='dc372b44-8fbc-4324-bfe1-a7699317a68e'></a>\n\n<::attestation: Stamp\nStamped\nReadable Text: EXHIBIT, Bhattacharya, 39, 10-27-13, ADDER\nA rectangular stamp with a thick black border, containing the word \"EXHIBIT\" at the top, followed by handwritten text \"Bhattacharya\", \"39\", and \"10-27-13\". The word \"ADDER\" is vertically oriented on the left side of the stamp. The stamp is centrally located in the image.::>\n\n<a id='78dc223a-9ccd-475c-af3c-12e803aeb7e7'></a>\n\n475 Half Day Road. Suite 500 Lincolnshire, Illinois 60069 Phone: 847-363-3000\n\n<a id='4bf7dce2-d168-46c0-a22d-76ff969c592f'></a>\n\nConfidential -- Subject to Protective Order\n\n<a id='f770cbf5-5959-40e8-978f-de2934d22bdc'></a>\n\nTAK-INDNDA-01273547\nProduced in MDL on 09/11/2012\n\n<a id='9934a470-964e-42fe-82c8-40083171a9e2'></a>\n\nSource: https://www.industrydocuments.ucsf.edu/docs/gyjf0226 P167900001",
            "chunks": [
                "a78105fa-ec68-4747-ae9c-a786030fb52e",
                "d9fc606c-46eb-44e2-a6f6-c178a420b8c1",
                "4237a84f-046e-4406-b226-80fd8e097100",
                "c3a05549-584b-494d-99c8-a707125bdd7f",
                "2b8fe70d-9bc3-4d31-b303-dec2a2d005c4",
                "144c5eef-182b-440c-8400-1b12e99e9bbf",
                "f0a88e60-5d05-4d2b-bb7f-2c736fbb322a",
                "b52c92a5-9e84-4015-b875-e9bed7561b94",
                "9429d7cc-5188-41be-a219-7de88f27b469",
                "dc372b44-8fbc-4324-bfe1-a7699317a68e",
                "78dc223a-9ccd-475c-af3c-12e803aeb7e7",
                "4bf7dce2-d168-46c0-a22d-76ff969c592f",
                "f770cbf5-5959-40e8-978f-de2934d22bdc",
                "9934a470-964e-42fe-82c8-40083171a9e2"
            ]
        }
    ],
    "grounding": {
        "a78105fa-ec68-4747-ae9c-a786030fb52e": {
            "box": {
                "left": 0.29892200231552124,
                "top": 0.03721657022833824,
                "right": 0.5878741145133972,
                "bottom": 0.09662145376205444
            },
            "page": 0,
            "type": "chunkLogo"
        },
        "d9fc606c-46eb-44e2-a6f6-c178a420b8c1": {
            "box": {
                "left": 0.11107990145683289,
                "top": 0.14249640703201294,
                "right": 0.26556310057640076,
                "bottom": 0.16295117139816284
            },
            "page": 0,
            "type": "chunkText"
        },
        "4237a84f-046e-4406-b226-80fd8e097100": {
            "box": {
                "left": 0.11240692436695099,
                "top": 0.18957534432411194,
                "right": 0.5743260383605957,
                "bottom": 0.31996098160743713
            },
            "page": 0,
            "type": "chunkText"
        },
        "c3a05549-584b-494d-99c8-a707125bdd7f": {
            "box": {
                "left": 0.11348368227481842,
                "top": 0.3289727568626404,
                "right": 0.5275429487228394,
                "bottom": 0.36630910634994507
            },
            "page": 0,
            "type": "chunkText"
        },
        "2b8fe70d-9bc3-4d31-b303-dec2a2d005c4": {
            "box": {
                "left": 0.4056697189807892,
                "top": 0.377616286277771,
                "right": 0.7431739568710327,
                "bottom": 0.3979176878929138
            },
            "page": 0,
            "type": "chunkText"
        },
        "144c5eef-182b-440c-8400-1b12e99e9bbf": {
            "box": {
                "left": 0.11296775937080383,
                "top": 0.39368584752082825,
                "right": 0.7782700061798096,
                "bottom": 0.5074049830436707
            },
            "page": 0,
            "type": "chunkText"
        },
        "f0a88e60-5d05-4d2b-bb7f-2c736fbb322a": {
            "box": {
                "left": 0.11335068941116333,
                "top": 0.5169841051101685,
                "right": 0.7794840931892395,
                "bottom": 0.6182799339294434
            },
            "page": 0,
            "type": "chunkText"
        },
        "b52c92a5-9e84-4015-b875-e9bed7561b94": {
            "box": {
                "left": 0.11507201194763184,
                "top": 0.6434211730957031,
                "right": 0.7783000469207764,
                "bottom": 0.7728440761566162
            },
            "page": 0,
            "type": "chunkText"
        },
        "9429d7cc-5188-41be-a219-7de88f27b469": {
            "box": {
                "left": 0.14175762236118317,
                "top": 0.7826957702636719,
                "right": 0.40267765522003174,
                "bottom": 0.8042774200439453
            },
            "page": 0,
            "type": "chunkText"
        },
        "dc372b44-8fbc-4324-bfe1-a7699317a68e": {
            "box": {
                "left": 0.7488587498664856,
                "top": 0.8026862144470215,
                "right": 0.9561989903450012,
                "bottom": 0.904842734336853
            },
            "page": 0,
            "type": "chunkAttestation"
        },
        "78dc223a-9ccd-475c-af3c-12e803aeb7e7": {
            "box": {
                "left": 0.16681012511253357,
                "top": 0.8754689693450928,
                "right": 0.7227685451507568,
                "bottom": 0.8921399116516113
            },
            "page": 0,
            "type": "chunkText"
        },
        "4bf7dce2-d168-46c0-a22d-76ff969c592f": {
            "box": {
                "left": 0.03399725258350372,
                "top": 0.922006368637085,
                "right": 0.3084467649459839,
                "bottom": 0.9397284984588623
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "f770cbf5-5959-40e8-978f-de2934d22bdc": {
            "box": {
                "left": 0.7016910314559937,
                "top": 0.9200401306152344,
                "right": 0.9225085973739624,
                "bottom": 0.9526458978652954
            },
            "page": 0,
            "type": "chunkText"
        },
        "9934a470-964e-42fe-82c8-40083171a9e2": {
            "box": {
                "left": 0.2208075225353241,
                "top": 0.9794996976852417,
                "right": 0.7793192863464355,
                "bottom": 0.9998054504394531
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "gyjf0226_1.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 5157,
        "credit_usage": 3.0,
        "job_id": "xijemzxyqmt7w6x8lrw5ior1l",
        "version": "dpt-2-20250919"
    }
}